ArticleTissue engineering. Part A2016
Semaphorin 3C Released from a Biocompatible Hydrogel Guides and Promotes Axonal Growth of Rodent and Human Dopaminergic Neurons.
Article in Tissue engineering. Part A, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Neuron-Derived Sema3B Facilitates Microglial Hematoma Clearance After Intracerebral Hemorrhage.Antioxidants (Basel, Switzerland) · 2026Article
- Supramolecular nanostructure mimics GDNF trophic effects in vitro on human dopaminergic neurons.NPJ Regenerative medicine · 2025Article
- The Use of Neurons Derived from Pluripotent Stem Cells to Study Nerve-Cancer Cell Interactions.International journal of molecular sciences · 2025Review
- Two- and Three-Dimensional In Vitro Models of Parkinson's and Alzheimer's Diseases: State-of-the-Art and Applications.International journal of molecular sciences · 2025Review
- Advances in hydrogel for diagnosis and treatment for Parkinson's disease.Frontiers in pharmacology · 2025Review
- Inorganic Nanoparticles-based Drug Delivery Systems for Neurodegenerative Diseases Therapy.Current pharmaceutical design · 2025Review
- Article
- Functionalized hydrogels in neural injury repairing.Frontiers in neuroscience · 2023Review
- Review
- Microfluidics for Neuronal Cell and Circuit Engineering.Chemical reviews · 2022Review
- Dynamic landscape of chromatin accessibility and transcriptomic changes during differentiation of human embryonic stem cells into dopaminergic neurons.Scientific reports · 2021Article
- Emerging hiPSC Models for Drug Discovery in Neurodegenerative Diseases.International journal of molecular sciences · 2021Review
- Regenerative Stem Cell Therapy for Neurodegenerative Diseases: An Overview.International journal of molecular sciences · 2021Review
- Hydrogels for neuroprotection and functional rewiring: a new era for brain engineering.Neural regeneration research · 2020Review
- Nanoparticle technology and stem cell therapy team up against neurodegenerative disorders.Advanced drug delivery reviews · 2019Review
- Classical differentiation protocols upregulate the expression of the axon guidance genes PLXNA2 and SEMA3C in SH-SY5Y neuroblastoma cells.Human cell · 2019Article
- Semaphorin 3C and Its Receptors in Cancer and Cancer Stem-Like Cells.Biomedicines · 2018Review
- Current drug design to target the Semaphorin/Neuropilin/Plexin complexes.Cell adhesion & migration · 2016Review
- Article
- Human Keratinocytes Adopt Neuronal Fates AfterCell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell therapy in experimental models of Parkinson's disease replaces the lost dopamine neurons (DAN), but we still need improved methods to guide dopaminergic axons (DAx) of grafted neurons to make proper connections. The protein Semaphorin 3C (Sema3C) attracts DAN axons and enhances their growth. In this work, we show that the hydrogel PuraMatrix, a self-assembling peptide-based matrix, incorporates Sema3C and releases it steadily during 4 weeks. We also tested if hydrogel-delivered Sema3C attracts DAx using a system of rat midbrain explants embedded in collagen gels. We show that Sema3C released by this hydrogel attracts DAx, in a similar way to pretectum, which is known to attract growing DAN axons. We assessed the effect of Sema3C on the growth of DAx using microfluidic devices. DAN from rat midbrain or those differentiated from human embryonic stem cells showed enhanced axonal extension when exposed to hydrogel-released Sema3C, similar to soluble Sema3C. Notably, DAN of human origin express the cognate Sema3C receptors, Neuropilin1 and Neuropilin2. These results show that PuraMatrix is able to incorporate and release Sema3C, and such delivery guides and promotes the axonal growth of DAN. This biocompatible hydrogel might be useful as a Sema3C carrier for in vivo studies in parkinsonian animal models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.